Guillaume Normand

Guillaume Normand

Company: Novartis

Job title: Director - Clinical Development


Panel Discussion: Evaluating the Current State of Play of Retinal Imaging Technologies Available for Ophthalmic Drug Developers 8:30 am

Evaluating how novel imaging modalities are being used to establish new and improved biomarkers for retinal disorders Unleashing the potentials of higher resolution technologies to translate into useful tools to determine disease activity and therapeutic efficacy Assessing the ability of novel technologies to validate retinal biomarkers for preclinical and clinical studies Read more

day: Day One

Evaluating the Potential of New Endpoints Derived From Advanced Imaging Technologies 9:30 am

Harnessing newer imaging modalities to provide indicators of therapeutic effect required for clinical progression Evaluating possible new endpoints in the retina based on current assessments of retinal disease pathologies Exploring how advancing knowledge in retinal disorders can be translated into novel endpoints that meet validation standardsRead more

day: Day Two

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.